{"id":"W2132550116","doi":"10.1093/annonc/mdf195","title":"Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels","year":2002,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":93,"is_retracted":false,"has_abstract":false,"ca_institutions":"BP (Canada); McGill University","funders":"","keywords":"Medicine; Refractory (planetary science); Renal cell carcinoma; Adverse effect; Internal medicine; Toxicity; Clinical trial; Cancer; Gastroenterology; Oncology; Carcinoma; Urology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002450558,0.001865232,0.003014359,0.0006176897,0.0007643484,0.001541979,0.001297164,0.002232818,0.003117623],"category_scores_gemma":[0.001516439,0.0008740283,0.002064706,0.0007470125,0.001464179,0.001331482,0.0004997684,0.005918066,0.0007777283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001354277,"about_ca_system_score_gemma":0.001604947,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00244099,"about_ca_topic_score_gemma":0.00342825,"domain_scores_codex":[0.999162,0.0003667799,0.00005358829,0.0001271191,0.00006784895,0.0002226904],"domain_scores_gemma":[0.9986277,0.0003872348,0.0001687826,0.0001373426,0.00006061871,0.0006184152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7707837,0.05093374,0.007385039,0.0006485869,0.003184708,0.0005366877,0.0005574407,0.00389233,0.03937202,0.000559187,0.003148306,0.1189983],"study_design_scores_gemma":[0.6744328,0.3105429,0.00677487,0.0000294951,0.0007145136,0.0003684457,0.00008636298,0.0008901675,0.003959403,0.0002087782,0.001941449,0.00005081456],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993042,0.002349368,0.0006967894,0.0006788914,0.0001321987,0.001066248,0.0007479488,0.00008562809,0.001200944],"genre_scores_gemma":[0.9860085,0.002981492,0.002470798,0.001196453,0.0002373018,0.001706148,0.002321672,0.00008442192,0.00299322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003117623,"threshold_uncertainty_score":0.01295996,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05781564707740489,"score_gpt":0.3455197344821135,"score_spread":0.2877040874047087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}